Dextrose
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Dextrose
- Generic name
- DEXTROSE MONOHYDRATE
- Manufacturer
- Medical Purchasing Solutions, LLC
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- ada63d44-3b37-b65d-e053-2a95a90aa088
- SPL ID
- faceeefa-0646-2e48-e053-6394a90a405f
- Version
- 2
- Effective date
- 2023-05-03
- Source export date
- 2026-09-28
- Source partition
- 9
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0009-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-09-28/6784607726c827491ceaeab30d843632e0660ee8008c535197be5ed9e1e52201/drug-label-0009-of-0014.json.zip
- Source manifest SHA-256
- cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
- Import run
- 20260929T050834Z
- Imported at
- 2026-09-29 06:03:52
| Harmonized routes |
|---|
| INTRAVENOUS |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | NDA | 019445 | derived:openfda.application_number |
| application number | NDA019445 | openfda.application_number | |
| brand name | Dextrose | openfda.brand_name | |
| generic name | DEXTROSE MONOHYDRATE | openfda.generic_name | |
| manufacturer name | Medical Purchasing Solutions, LLC | openfda.manufacturer_name | |
| ndc | package | 71872-7214-1 | openfda.package_ndc |
| ndc | product | 71872-7214 | openfda.product_ndc |
| ndc11 | package | 71872721401 | derived:openfda.package_ndc |
| rxcui | 727518 | openfda.rxcui | |
| spl id | faceeefa-0646-2e48-e053-6394a90a405f | id | |
| spl set id | ada63d44-3b37-b65d-e053-2a95a90aa088 | set_id | |
| unii | LX22YL083G | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNINGS 25% Dextrose Injection, USP is hypertonic and may cause phlebitis and thrombosis at the site of injection. Significant hyperglycemia and possible hyperosmolar syndrome may result from too rapid administration. The physician should be aware of the symptoms of hyperosmolar syndrome, such as loss of consciousness.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
ADVERSE REACTIONS Hyperosmolar syndrome, resulting from excessively rapid administration of concentrated dextrose may cause mental confusion and/or loss of consciousness. Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection and extravasation. If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures, and save the remainder of the fluid for examination if deemed necessary.
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.